Mackenzie Financial Corp raised its stake in shares of Repligen Corporation (NASDAQ:RGEN) by 29.8% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 201,917 shares of the biotechnology company’s stock after buying an additional 46,300 shares during the period. Mackenzie Financial Corp owned 0.60% of Repligen Corporation worth $7,107,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also modified their holdings of the stock. Marshall Wace North America L.P. purchased a new position in Repligen Corporation during the first quarter valued at $9,006,000. MARSHALL WACE ASIA Ltd bought a new stake in shares of Repligen Corporation during the first quarter valued at approximately $9,006,000. TimesSquare Capital Management LLC increased its stake in shares of Repligen Corporation by 35.1% in the first quarter. TimesSquare Capital Management LLC now owns 1,970,725 shares of the biotechnology company’s stock valued at $69,370,000 after buying an additional 512,300 shares during the period. Thrivent Financial For Lutherans increased its stake in shares of Repligen Corporation by 4.3% in the first quarter. Thrivent Financial For Lutherans now owns 18,850 shares of the biotechnology company’s stock valued at $664,000 after buying an additional 780 shares during the period. Finally, Legal & General Group Plc increased its stake in shares of Repligen Corporation by 1.5% in the first quarter. Legal & General Group Plc now owns 59,556 shares of the biotechnology company’s stock valued at $2,094,000 after buying an additional 857 shares during the period. 98.46% of the stock is currently owned by institutional investors.
Repligen Corporation (RGEN) traded down 0.28% on Tuesday, reaching $39.15. The company had a trading volume of 292,186 shares. The stock has a market capitalization of $1.33 billion, a P/E ratio of 103.30 and a beta of 1.30. Repligen Corporation has a 12-month low of $21.95 and a 12-month high of $40.48. The stock’s 50-day moving average price is $38.60 and its 200-day moving average price is $33.99.
Repligen Corporation (NASDAQ:RGEN) last announced its quarterly earnings results on Thursday, May 4th. The biotechnology company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of $0.13 by $0.02. Repligen Corporation had a return on equity of 9.57% and a net margin of 11.93%. The company had revenue of $30.59 million during the quarter, compared to analyst estimates of $29.28 million. During the same period in the prior year, the company earned $0.12 earnings per share. The firm’s revenue was up 21.9% on a year-over-year basis. On average, equities research analysts anticipate that Repligen Corporation will post $0.56 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Mackenzie Financial Corp Increases Position in Repligen Corporation (RGEN)” was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://sportsperspectives.com/2017/06/20/mackenzie-financial-corp-boosts-position-in-repligen-corporation-rgen-updated.html.
RGEN has been the topic of a number of recent research reports. BidaskClub downgraded shares of Repligen Corporation from a “strong-buy” rating to a “buy” rating in a report on Wednesday, June 14th. Zacks Investment Research upgraded shares of Repligen Corporation from a “hold” rating to a “buy” rating and set a $42.00 target price on the stock in a report on Wednesday, June 14th. Finally, First Analysis reaffirmed an “equal weight” rating and set a $40.00 price objective on shares of Repligen Corporation in a research report on Friday, April 21st. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $37.25.
About Repligen Corporation
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.
Receive News & Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related companies with MarketBeat.com's FREE daily email newsletter.